{"id":5104,"date":"2021-12-11T09:59:00","date_gmt":"2021-12-11T09:59:00","guid":{"rendered":"https:\/\/cdafound.org\/?p=5104"},"modified":"2025-01-14T21:36:23","modified_gmt":"2025-01-14T21:36:23","slug":"progress-towards-achieving-viral-hepatitis-b-and-c-elimination-in-the-asia-and-pacific-region-results-from-modelling-and-global-reporting","status":"publish","type":"post","link":"https:\/\/cdafound.org\/fr\/progress-towards-achieving-viral-hepatitis-b-and-c-elimination-in-the-asia-and-pacific-region-results-from-modelling-and-global-reporting\/","title":{"rendered":"Progr\u00e8s vers l&#039;\u00e9limination des h\u00e9patites virales B et C dans la r\u00e9gion Asie et Pacifique\u00a0: r\u00e9sultats de la mod\u00e9lisation et des rapports mondiaux"},"content":{"rendered":"<h2 class=\"wp-block-heading\">R\u00e9sum\u00e9<\/h2>\n\n\n\n<p>En 2016, les pays d&#039;Asie et du Pacifique ont approuv\u00e9 des plans d&#039;action pour atteindre les objectifs d&#039;\u00e9limination de l&#039;h\u00e9patite virale fix\u00e9s dans la Strat\u00e9gie mondiale du secteur de la sant\u00e9 (GHSS) contre l&#039;h\u00e9patite virale 2016-2021. Nous examinons les progr\u00e8s de la r\u00e9gion en mod\u00e9lisant la charge de morbidit\u00e9 et en construisant la cascade des soins. Entre 2015 et 2020, la pr\u00e9valence chronique du VHB est pass\u00e9e de 4,69% \u00e0 4,30%, et la pr\u00e9valence du VHC est pass\u00e9e de 0,64% \u00e0 0,58%. La r\u00e9gion a atteint l&#039;objectif 2020 de r\u00e9duction de l&#039;incidence du 30% pour le VHB, tandis que l&#039;incidence du VHC a diminu\u00e9 de 6%. L&#039;incidence du carcinome h\u00e9patocellulaire pour le VHB et le VHC a augment\u00e9 de 9% et 7%, respectivement. Les d\u00e9c\u00e8s li\u00e9s au foie dus au VHB ont augment\u00e9 de 8% et la mortalit\u00e9 attribuable au VHC a atteint un plateau. D&#039;importantes lacunes en mati\u00e8re de d\u00e9pistage et de traitement subsistaient en 2019\u00a0: seulement 13% d&#039;infections chroniques par le VHB ont \u00e9t\u00e9 diagnostiqu\u00e9es et 25% trait\u00e9es\u00a0; 21% d&#039;infection chronique par le VHC ont \u00e9t\u00e9 diagnostiqu\u00e9s et 11% trait\u00e9s. L&#039;h\u00e9patite virale doit devenir une priorit\u00e9 nationale avec un financement ad\u00e9quat pour atteindre les objectifs d&#039;\u00e9limination d&#039;ici 2030.<\/p>\n\n\n\n<p><strong>Pays\/Territoires\u00a0:<\/strong> Asie et Pacifique<\/p>\n\n\n\n<div class=\"wp-block-buttons is-content-justification-center is-layout-flex wp-block-buttons-is-layout-flex\">\n<div class=\"wp-block-button is-style-outline is-style-outline--1\"><a class=\"wp-block-button__link has-text-color wp-element-button\" href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/34894047\/\" style=\"border-radius:6px;color:#951b23\" target=\"_blank\" rel=\"noreferrer noopener\">Lire le rapport complet<\/a><\/div>\n<\/div>","protected":false},"excerpt":{"rendered":"<p>Summary In 2016, Asia and Pacific countries endorsed action plans for reaching viral hepatitis elimination targets set in the Global Health Sector Strategy (GHSS) for Viral Hepatitis 2016-2021. We examine the region&#8217;s progress by modelling disease burden and constructing the cascade of care. Between 2015 and 2020, chronic HBV prevalence declined from 4.69% to 4.30%, [&hellip;]<\/p>\n","protected":false},"author":24,"featured_media":3486,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[9],"tags":[31,21,10,12],"publication-author":[488,490,491,489,487,496,495,494,497,492,493],"class_list":["post-5104","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-publication","tag-elimination","tag-hbv","tag-hcv","tag-modelling","publication-author-blach-s","publication-author-chan-p","publication-author-fuqiang-c","publication-author-ishikawa-n","publication-author-le-lv","publication-author-low-beer-d","publication-author-mangadan-konath-n","publication-author-razavi-h","publication-author-razavi-shearer-d","publication-author-rewari-b","publication-author-sharma-m"],"acf":[],"_links":{"self":[{"href":"https:\/\/cdafound.org\/fr\/wp-json\/wp\/v2\/posts\/5104","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cdafound.org\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cdafound.org\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cdafound.org\/fr\/wp-json\/wp\/v2\/users\/24"}],"replies":[{"embeddable":true,"href":"https:\/\/cdafound.org\/fr\/wp-json\/wp\/v2\/comments?post=5104"}],"version-history":[{"count":2,"href":"https:\/\/cdafound.org\/fr\/wp-json\/wp\/v2\/posts\/5104\/revisions"}],"predecessor-version":[{"id":7437,"href":"https:\/\/cdafound.org\/fr\/wp-json\/wp\/v2\/posts\/5104\/revisions\/7437"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cdafound.org\/fr\/wp-json\/wp\/v2\/media\/3486"}],"wp:attachment":[{"href":"https:\/\/cdafound.org\/fr\/wp-json\/wp\/v2\/media?parent=5104"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cdafound.org\/fr\/wp-json\/wp\/v2\/categories?post=5104"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cdafound.org\/fr\/wp-json\/wp\/v2\/tags?post=5104"},{"taxonomy":"publication-author","embeddable":true,"href":"https:\/\/cdafound.org\/fr\/wp-json\/wp\/v2\/publication-author?post=5104"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}